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a b s t r a c t
Background: There is increasing interest in treating oligometastatic non-small cell lung cancer (NSCLC)
patients with stereotactic radiation. We aimed to address whether patients definitively treated with syn-
chronous thoracic stereotactic body radiation therapy (SBRT) and brain stereotactic radiosurgery (SRS)
had favorable outcomes with local therapy.
Materials and methods: We reviewed a database of patients receiving lung SBRT as well as a database for
brain metastasis patients treated with SRS between June 2004 and January 2016. We selected for cT1-
2aN0M1 NSCLC patients with brain metastases and calculated their overall survival (OS), freedom from
progression (FFP), and local control (LC) rates.
Results: Six patients had oligometastatic NSCLC with 1–3 synchronous brain metastases treated with
lung SBRT and brain SRS. No patients received immunotherapy and two-thirds did not receive systemic
therapy. Median follow-up was 9 months for the entire cohort (range, 2–95 months) and 95 months for
the surviving patient. Median OS was 12.4 months (95% confidence interval [CI], 7–18 months). At 1 year,
patients had 67% OS (95% CI, 29–100%), 17% FFP (95% CI, 0–46%), and 100% LC. Their brain disease had 80%
1-year LC (95% CI, 45–100%) and 53% 1-year FFP (95% CI, 5–100%). Two patients had no distant progres-
sion, two had brain progression, one had adrenal gland progression, and one had bone and liver progres-
sion.
Conclusion: In patients presenting with oligometastatic lung cancer limited to the brain, treatment with
both lung SBRT and brain SRS achieves good LC of all sites with encouraging OS.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Lung cancer continues to be the number one cause of cancer-
related death in the United States [1]. Among non-small cell lung
cancer (NSCLC) patients, half initially present with metastatic dis-
ease, with the central nervous system (CNS) being the first site of
failure in up to one-third of patients [2]. Stereotactic radiosurgery
(SRS) has emerged as a preferred treatment option for controlling
brain metastases [3].
With improvements to chemotherapeutic and supportive care
agents, overall survival in patients with metastatic disease con-
tinues to improve. As such, there has been renewed interest in
radiotherapy for primary thoracic disease. This trend is reflected
in national guidelines, such as the National Comprehensive Can-
cer Network, which advocates primary treatment in patients
with locally advanced thoracic disease and limited non-
thoracic metastatic burden [4]. While brain metastases in
patients with otherwise early-stage disease is rare, treating tho-
racic disease with stereotactic body radiation therapy (SBRT)
and brain disease with SRS remains unexplored. We aimed to
clarify the combined effect of lung SBRT and brain SRS in this
patient cohort.
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2. Patients and methods
2.1. Eligibility criteria
Patients treated at the Siteman Cancer Center in St. Louis were
identified from two institutional review board-approved data-
bases. One was for patients receiving thoracic SBRT and the other
was for patients receiving SRS for brain metastases. Patients were
enrolled in the databases between June 2004 and January 2016.
Patient, disease, and treatment information were extracted from
the medical record in a retrospective fashion. The databases were
queried to find a cohort of patients present in both databases
who had T1a-T2aN0M1 NSCLC secondary to synchronous brain
metastases at the time of diagnosis. Synchronous brain metastases
were defined as tumors treated with brain-directed SRS within
3 months of thoracic SBRT. Patients with stage I NSCLC who later
developed brain metastases and received salvage SRS were
excluded from analysis as were patients who had other non-CNS
metastatic sites. All eligible patients had received PET or CT chest
and a brain MRI.
2.2. Lung SBRT
SBRT planning and delivery were performed as previously
described [5]. For peripheral lesions, patients received 5400 cGy
in 3 every-other-day fractions. For lesions within 2 cm of the prox-
imal bronchial tree, the mediastinum, or the pericardium, patients
received 5000–5500 cGy in 5 fractions. Normal tissue dose limits
were set in accordance to RTOG 0813[6] and RTOG 0236 [7].
2.3. Brain SRS
Single-fraction SRS planning and delivery was performed as
previously described [8]. The radiation doses were generally 20–
24 Gy for tumors  2 cm, 18 Gy for tumors 2.1–3 cm, and 15 Gy
for tumors > 3 cm according to RTOG 90–05 [9].
2.4. Follow-up
Patients were followed every 3–4 months with CT or PET/CT
imaging for thoracic disease and every 2–3 months with a brain
MRI for CNS disease. If there was low suspicion for disease progres-
sion after 2 years, patients were followed in 6-month intervals.
2.5. Evaluation
Overall survival (OS), freedom from progression (FFP), and local
control (LC) were calculated from the date of the first fraction of
radiation. Progression was defined as any local, regional, or distant
progression that occurred after the completion of radiation ther-
apy. Local failure for lung tumors was defined as in-field progres-
sion that occurred after the completion of radiation therapy.
Local failure for brain metastases was defined as an increase in size
of the treated lesion at any time after SRS unless advanced imaging
or pathology indicated radiation necrosis. Patients that died of
causes other than disease progression or treatment complications
were censored and not counted as progression or local failure.
2.6. Statistical analysis
Cumulative rates of OS, FFP, and LC were calculated using
Kaplan-Meier survival analysis. All statistical analyses were per-




Patient characteristics are listed in Table 1. 6 patients had oligo-
metastatic disease treated with SBRT for primary lung cancer and
SRS for 1–3 synchronous brain metastases. Among these patients,
2 received whole brain radiation therapy (WBRT) prior to an SRS
boost and 2 received adjuvant chemotherapy (Table 2). Median
follow-up was 9 months for oligometastatic group (range, 2–
95 months). Median age at diagnosis was 76.6 years (range,
63.2–86.7) and median age-adjusted Charlson Comorbidity Score
was 11 (range, 9–12). Four patients were former smokers, five
had no previous cancer history, and all six had an ECOG perfor-
mance status of 1 or better. Their lung tumors had a median tumor
diameter of 3.2 cm and their brain metastases had a median tumor
volume of 1.3 cm3.
Table 1
Patient characteristics at diagnosis.
Patient Characteristics
Sample size 6 patients















Smoking history (pack years), mean 33.8
Thoracic Tumor Characteristics





1–1.9 cm 1 (17%)
2–2.9 cm 2 (33%)
3–3. cm 1 (17%)












00.9 cm3 4 (44%)
1–2.9 cm3 3 (33%)
3–4.9 cm3 0 (0%)
5–8 cm3 2 (22%)
ECOG = Eastern Cooperative Oncology Group.
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3.2. Clinical outcomes
Median OS was 12.4 months (95% CI, 6.8–18.0 months) in this
patient cohort, with one patient remaining alive after 95 months
of follow-up. The 1-year rates were 67% for OS (95% confidence
interval [CI], 29–100%), 17% for FFP (95% CI, 0–46%), and 100% for
thoracic LC (Fig. 1). They had 80% 1-year CNS LC (95% CI, 45–
100%) and 53% CNS FFP (95% CI, 5–100%). Two of the patients
had no distant progression: one remains alive at 95 months and
the other died at 1.8 months. Of the remaining patients, two had
progression in their brain at 2.3 and 10.1 months, one had progres-
sion to their adrenal gland at 6.8 months and one had progression
to their bones and liver at 5.7 months (Table 2). The only docu-
mented toxicities were two grade 2 cases of chest wall toxicity
(33%).
4. Discussion
We report the results of series of six patients with oligometa-
static NSCLC with brain metastasis treated with lung SBRT and
brain SRS. In general, these patients had a limited burden of tho-
racic and CNS disease with a good performance status, but they
had high baseline comorbidities. Four of the six patients survived
for longer than one year, with one patients still surviving at almost
8 years of follow-up. There were no cases of local thoracic failure
and only two cases of local CNS failure. These results reflect favor-
ably on national guideline recommendations to offer definitive
management to both primary and metastatic sites. Unfortunately,
we noted a significant rate of disease progression in this cohort,
with all patients progressing by 18 months. This is not surprising
given the presence of metastatic disease at baseline.
Five published studies have examined definitive management
of CNS and thoracic disease in oligometastatic lung cancer. Table 3
summarizes the results of these studies.
Yang et al. [10] examined a group of 31 patients who received
SRS for their brain metastases. 16 of the patients received thoracic
surgery with or without adjuvant chemotherapy or lung radiation.
They had a median OS of 64.9 months and a 5-year OS rate of
87.5%. The other 15 patients received either chemotherapy, lung
radiation, or both. These patients had a median OS of 18.1 months
and a 5-year OS of 22.5%. In the second group with less favorable
outcomes, only 3 of the patients received lung radiation. The
remaining patients in this group received chemotherapy alone.
Hu et al. [11] had a subgroup of 31 patients treated with brain
SRS (n = 24) or brain SRS plus WBRT (n = 7) and radiation,
chemotherapy, or both for their primary lung cancer. This cohort
had a median OS of 7.4 months compared to 12.4 months among
the patients in our study. Their results demonstrated inferior out-
comes than our study because they included patients who were a
thoracic stage I-III, unlike our study that included only thoracic
stage I patients. They did not create a separate subgroup that
received only stereotactic body radiation for both their brain
metastases and their lung cancer.
Flannery et al. [12] reported on 26 patients treated definitively
for thoracic disease and brain metastases. All the patients received
SRS with or without adjuvant WBRT. For their thoracic disease, 9
patients received chemoradiation, 12 patients received surgical
resection with or without adjuvant chemotherapy, and 5 received
surgery and chemoradiation. The inclusion of surgical candidates
in their study caused their patients to have a higher median OS
of 26.4 months compared to 12.4 months in our study and a 5-
year OS rate of 34.6% compared to 17% in our study.
Gray et al. [13] had a less comparable group of 38 patients who
received surgery, radiation, and/or chemotherapy for both their
primary lung cancer and their brain metastases. They did not sep-
arate patients based on their treatment modality. Like Flannery
et al., this study included surgical candidates, which likely caused
their patient cohort to have a higher median OS of 26.4 months
compared to our study.
Lo et al. [14] had subset of 3 patients who received surgery for
primary lung cancers and SRS for brain metastases. They found a
median OS of 17.3 months.
These studies demonstrate that delivering local therapy to both
the primary tumor and the metastases improves patient outcomes
in oligometastatic NSCLC cancer patients with brain metastases. A
number of these studies reported a median OS of at least one year
with a subset of patients surviving several years with aggressive
management of both thoracic and CNS disease. This suggests that
a subset of oligometastatic patients may achieve survival compara-
ble to more early-stage patients.
The advantage of this study is that the patient cohort includes
those who received both definitive lung SBRT and brain SRS. Unlike
Table 2
Clinical outcomes.
Patient # of Brain Mets WBRT? Chemo? Location of progression Time to progression Local CNS failure? CNS Progression?
1 1 No No – – Yes, 26.4 mo. No
2 3 Yes No – – No No
3 1 Yes Yes Brain 10.1 mo. No Yes, 10.1 mo.
4 2 No No Adrenal gland 6.8 mo. No No
5 1 No Yes Brain 2.3 mo. Yes, 2.3 mo. Yes, 2.3 mo.
6 1 No No Bone, Liver 5.7 mo. No No
CNS = central nervous system. WBRT = whole brain radiation therapy.
Fig. 1. Overall survival (OS) and freedom from progression (FFP). Kaplan-Meier
survival analysis was performed.
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other studies, patients who received either surgical resection,
conventionally-fractionated thoracic radiation, or chemotherapy
alone were excluded. As a result, this cohort accurately reflects
outcomes in non-surgical candidates with limited metastatic dis-
ease in the modern era.
One limitation to this study is that even though it had one of the
larger sample sizes of exclusively lung SBRT and brain SRS patients,
the small sample size limited the generalizability of the results.
Another limitation was that the oligometastatic patient group
was heterogeneous with respect to whether patients received
chemotherapy or WBRT. These varied according to the patient’s
specific disease burden, provider preference, and patient prefer-
ence and could not be controlled retrospectively.
Advances in SBRT and brain SRS have revolutionized the treat-
ment of oligometastatic lung cancer and may be offered to more
patients moving forward. Several phase II randomized control tri-
als studies have tested the upper limit for the number of oligome-
tastatic sites that can be targeted using local stereotactic radiation
therapy. Gomez et al. [15] included NSCLC patients with up to
three sites of metastatic disease and Iyenger et al. [16] included
NSCLC patients with up to five sites of metastases. Both of these
papers found significantly higher PFS in patients treated with adju-
vant stereotactic radiation compared to patients who only received
first-line systemic therapy. These results have also been shown in
patients with other primary cancers as well. In the SABR-COMET
trial [17], which did not select for a specific primary cancer histol-
ogy, oligometastatic cancer patients with up to 5 metastases had
significantly improved PFS and OS. As the data for treatment of oli-
gometastatic disease matures, SBRT and SRS are likely to play lar-
ger roles in patients who were previously excluded from local
therapy.
5. Conclusions
In oligometastatic lung cancer patients secondary to brain
metastases, local treatment of both the primary lesion and the
metastases with lung SBRT and brain SRS, respectively, lead to
favorable OS outcomes. Lung SBRT and brain SRS achieved excel-
lent LC rates with well-tolerated toxicities. These results are con-
sistent with what other studies have found and support the use
of stereotactic radiation therapy for NSCLC patients with
oligometastases.
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Table 3
Treatment modalities and clinical outcomes of oligometastatic NSCLC patients with solitary brain metastases.
Authors Brain Treatment Lung Treatment Sample Size Median OS (months) 1-yr OS Rate 5-yr OS Rate
Hu et al. SRS ± WBRT Rad and/or Chemo 31 7.4 – –
Flannery et al. SRS ± WBRT Surg or rad ± Chemo 26 26.4 – 35%
Yang et al. SRS Surgery ± Chemo ± Rad 16 64.9 100% 88%
Chemo and/or Rad 15 18.1 66.7% 23%
Gray et al. Surg, SRS, and/or WBRT Surg, Chemo, and/or Rad 38 26.4 71% 29%
Lo et al. SRS Surgery 3 17.3 67% 33%
Current Study SRS ± WBRT SBRT 6 12.4 67% 17%
OS = overall survival. SBRT = stereotactic body radiation therapy. SRS = stereotactic radiosurgery. WBRT = whole brain radiation therapy.
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